O-GlcNAcylation Ameliorates the Pathological Manifestations of Alzheimer’s Disease by Inhibiting Necroptosis
O-GlcNAcylation (O-linked β-N-acetylglucosaminylation) is notably decreased in Alzheimer's disease (AD) [...]
O-GlcNAcylation (O-linked β-N-acetylglucosaminylation) is notably decreased in Alzheimer's disease (AD) [...]
Deposition of hyperphosphorylated and aggregated tau protein in the central [...]
Inhibition of O-GlcNAcase (OGA) has emerged as a promising therapeutic [...]
[18F]MK-8553 is a high affinity, selective OGA inhibitor with properties [...]
Advances Novel Tau-directed Strategy for Treating Neurodegenerative Disease Phase 1 [...]
Apr 18, 2016 – Alectos Therapeutics partner Merck, known as MSD [...]
Neurofibrillary tangles (NFTs) made up of aggregated tau protein have [...]
Vancouver, British Columbia (December 12, 2014) – Alectos Therapeutics Inc. [...]
Oct 26, 2014 – Alectos today announced publication of preclinical [...]
BACKGROUND: Amyloid plaques and neurofibrillary tangles (NFTs) are the defining [...]